Expression of estrogen receptor variants
- 1 January 1993
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 53 (S17G) , 194-197
- https://doi.org/10.1002/jcb.240531135
Abstract
Recent data suggest that the expression of estrogen receptor (ER) variants may be common in clinical breast cancer. The significance of their expression is complicated by the fact that they are often coexpressed with wild-type ER in the same tumor. We have focused upon one such ER variant which lacks exon 5 within the hormone binding domain of the receptor. This deletion introduces a stop codon, resulting in a truncated ER of 40 kDa which is unable to bind hormone. We have been exploring the hypothesis that this variant may contribute to clinical antiestrogen resistance. Coexpression of the exon 5 variant along with wild-type ER in MCF-7 human breast cancer cells confers resistance to the commonly used antiestrogen, tamoxifen. In addition, we have observed that some metastatic breast lesions overexpress exon 5 ER deletional variant transcripts. We conclude that differences in the relative amounts of several ER variants in the same tumor may interact to determine hormonal responsiveness and metastatic behavior.Keywords
This publication has 6 references indexed in Scilit:
- Structure and Function of the Estrogen ReceptorAnnals of the New York Academy of Sciences, 1993
- Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination.Journal of Biological Chemistry, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-HydroxytamoxifenJNCI Journal of the National Cancer Institute, 1991
- Functional domains of the human estrogen receptorCell, 1987